Please assess the completion status of the following clinical trial:

Trial Title: Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-metastatic prostate cancer~* Men to receive Gonadotropin-releasing Hormone-agonist therapy~Exclusion Criteria:~* Other cancers except skin cancer~* Evidence of metabolic bone disease~* Prior use of bisphosphonates

- Gender: MALE
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Risedronate (Type: EXPERIMENTAL): 35 mg by mouth every week as directed
- risedronate placebo tablet (Type: PLACEBO_COMPARATOR): Calcium and vitamin D

Based on this trial design, predict the completion outcome and termination type (if applicable).